| Project/Area Number |
18K16159
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54020:Connective tissue disease and allergy-related
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Maeda Shinji 名古屋市立大学, 医薬学総合研究院(医学), 講師 (80381854)
|
|---|
| Project Period (FY) |
2018-04-01 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 多機能性T細胞 / IL-2 / 自己免疫疾患 / ヒト化マウス / T細胞受容体シグナル / CTLA-4 / Mass Cytometry / Th1/17 / x-GVHD / Treg / T細胞 |
|---|
| Outline of Final Research Achievements |
In this study, we aimed to reconstruct autoimmune tolerance and achieve drug-free remission in rheumatic and collagen diseases. Using a humanized mouse model treated with IL-2 and IL-2 antibody complex, we analyzed in detail the interaction and balance between polyfunctional T cells (PFC-T cells) and regulatory T cells (Tregs). Notably, we confirmed that sustained stimulation by IL-2 and the regulation of T cell receptor antigen signals play a crucial role in the balance between inflammation suppression and immune regulation. These findings contribute to the identification of new therapeutic targets for the fundamental treatment of autoimmune diseases and provide a foundation for future clinical applications.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、自己免疫疾患治療の新たな可能性を開拓しました。特に、炎症性多機能性T細胞の調節に焦点を当てることで、ドラッグフリー寛解の達成へとつながる治療戦略の基盤になる成果です。将来的に自己免疫疾患患者の治療の向上に寄与するだけでなく、治療コストの削減にも繋がりうる、基礎研究と臨床応用の架け橋としての役割も果たしています。
|
